Produced principally for unit EME144 (Science education 1) offered by the Faculty of Education's School of Scientific and Developmental Studies in Education in Deakin University's Open Campus Program. Campus Program.
Global recessions and structural economic shifts are motivating government and business leaders worldwide to increasingly look to "their" universities to stimulate regional development and to contribute to national competiveness. The challenge is clear and the question is pressing: How will universities respond? This book presents in-depth case narratives of ten universities from Norway, Finland, Sweden, UK, and the U.S. that have overcome significant challenges to develop programs and activities to commercialize scientific research, launch entrepreneurial degree programs, establish industry partnerships, and build entrepreneurial cultures and ecosystems. The universities are quite diverse: large and small; teaching and research focused; internationally recognized and relatively new; located in major cities and in emerging regions. Each case narrative describes challenges overcome, actions taken, and resulting accomplishments. This volume will be of interest to policymakers and university administrators as well as researchers and students interested in how different programs and activities can promote university entrepreneurship while contributing to economic growth in developed and developing economies.
Comprehensive directory of databases as well as services "involved in the production and distribution of information in electronic form." There is a detailed subject index and function/service classification as well as name, keyword, and geographical location indexes.
Immunotherapy is a clinically proven concept to prevent and treat diverse diseases. Therapeutic monoclonal antibodies (mAb) have transformed cancer patient survival and the quality of life for patients with inflammatory and autoimmune diseases. Vaccination with attenuated viruses or microbial virulence factors is a validated strategy to control infectious disease and has eradicated the global pandemic Smallpox infection. Recently, the concept of encoding transgenes, such as the receptor-binding COVID-19 spike protein, cytokines, antibodies, or immunogenic tumor antigens into non-viral or viral vectors has been validated as a powerful means to achieve vaccination for protection against pandemic infections, and cancer immunotherapy respectively. For certain immunotherapeutic targets and mechanisms, vector-based targeting offers distinct advantages over the traditional protein format. For example, in cancer immunotherapy vectorization may enable local delivery, production, and tumor-enriched exposure of powerful immune-modulatory antibodies, for example anti-CTLA-4 or anti-CD28 that are too toxic to allow full therapeutic dosing upon systemic administration.